Table 2.
Clinicopathological characteristics of the discovery and validation cohorts.
| Characteristics | Cohorts |
||
|---|---|---|---|
| Discovery cohort | Validation cohort | Entire cohort | |
| (N = 85) | (N = 42) | (N = 127) | |
| Cases - Frequency (%) | |||
| MIS-C | 29 (34.1%) | 14 (33.3%) | 43 (33.9%) |
| Non-MIS-C | 56 (65.9%) | 28 (66.7%) | 84 (66.1%) |
| Gender - Frequency (%) | |||
| Female | 36 (42.4%) | 22 (52.4%) | 58 (45.7%) |
| Male | 49 (57.6%) | 20 (47.6%) | 69 (54.3%) |
| Age (years) - Median [range] | 9.0 [0–17] | 7.5 [0–16] | 8.0 [0 - 17] |
| Age group- Frequency (%) | |||
| ≤2 yr | 11 (12.9%) | 3 (7.1%) | 14 (11.0%) |
| 3–5 yr | 11 (12.9%) | 13 (31.0%) | 24 (18.9%) |
| 6–9 yr | 22 (25.9%) | 12 (28.6%) | 34 (26.8%) |
| 10–13 yr | 23 (27.1%) | 7 (16.7%) | 30 (23.6%) |
| 14–18 yr | 18 (21.2%) | 7 (16.7%) | 25 (19.7%) |
| Ethnicity - Frequency (%) | |||
| West-Eurasia | 61 (71.8%) | 25 (59.5%) | 86 (67.7%) |
| Central-South America | 7 (8.2%) | 4 (9.5%) | 11 (8.7%) |
| African | 4 (4.7%) | 2 (4.8%) | 6 (4.7%) |
| Unknown | 13 (15.3%) | 11 (26.2%) | 24 (18.9%) |